No formal Medicube lawsuit appears to have been filed as of mid-2026, but the brand and its parent company, APR Corporation, are dealing with regulatory actions and consumer safety reports across three countries: an advertising suspension in South Korea, public health warnings in the Philippines, adverse event reports filed with the U.S. Food and Drug Administration, and dozens of unresolved complaints at the Better Business Bureau.
U.S. FDA Adverse Event Reports on the Age-R Booster Pro
The Medicube device drawing the most regulatory attention in the United States is the Age-R Booster Pro, a handheld skincare tool marketed for facial contouring, microcurrent therapy, and elasticity care. A report received by the FDA’s MAUDE database in August 2025 described a consumer who developed intense facial nerve pain, persistent skin irritation, and inflammatory breakouts requiring medical attention after using the device as directed.1U.S. FDA. MAUDE Adverse Event Report MW5175339 The listed clinical effects included nerve damage, scar tissue, sleep dysfunction, muscle spasms, and skin inflammation.
The consumer who filed that report alleged Medicube was marketing the Age-R Booster Pro as a medical device without proper FDA registration or 510(k) clearance. A separate MAUDE report made a similar allegation, claiming a search of the FDA device registration database showed no record of Medicube products being registered as Class II devices.2U.S. FDA. MAUDE Adverse Event Report MW5174314 Neither report includes independent FDA confirmation of the device’s registration status. They document consumer allegations, not agency findings.
Bell’s Palsy Reports and Medicube’s Response
At least two consumers have reported on social media that use of the Age-R Booster Pro triggered symptoms consistent with Bell’s palsy. One user described drooping in her eyelid, pupil dilation, and impaired vision she attributed to inflammation from the device. A second reported facial paralysis on one side that affected her speech and lip position.1U.S. FDA. MAUDE Adverse Event Report MW5175339
Medicube has denied any link between the device and these injuries. The company said the device’s intensity is insufficient to damage nerves and cited its own clinical trials in support, and it updated the product listing to deny that the device causes nerve injuries. No formal lawsuits over these reports appear to have been filed as of mid-2026, and publicly available information is not sufficient to establish whether the device caused or contributed to the reported conditions.
Other consumer reports raise separate safety concerns. In April 2025, a Better Business Bureau complaint said an Age-R Booster Pro began sparking, burned the user’s hand, and damaged an electrical outlet. Another complaint alleged that a product bought through Medicube’s TikTok store contained tiny glass shards that caused multiple facial cuts.3Better Business Bureau. Medicube BBB Complaints Both complaints were left unanswered.
South Korea’s Advertising Suspension
South Korea’s Ministry of Food and Drug Safety ordered Medicube to suspend advertising for two products, the One Day Exosome Pore Ampoule 2000 and the One Day Exosome Shot Pore Ampoule 7500, until June 8, 2026. The agency cited violations of the Cosmetics Act, finding that Medicube’s marketing language could mislead consumers into believing the cosmetics were pharmaceutical products.4TheKShop. Medicube Ordered to Suspend Advertising in Korea
Regulators prohibited claims that products could regenerate skin, repair cells, or dramatically shrink pores, and specifically targeted general “EXO” branding and language that might lead consumers to believe products contain human-derived stem cells.5Forte Shopping. Medicube and Dr. G Ads Suspended Banned phrases also included “doctor recommended,” “hospital exclusive,” “skin regeneration,” and “anti-inflammatory.”6Chosun Biz. MFDS Crackdown on Cosmetic Advertising
Philippine FDA Warnings
In May 2025, the Philippine Food and Drug Administration issued public health warnings against two Medicube products, classifying them as unauthorized cosmetics that had not received Certificates of Product Notification. Advisory No. 2025-0548 targeted the Medicube Collagen Glow Bubble Serum, and Advisory No. 2025-0549 targeted the Medicube PDRN Pink Peptide Serum.7Philippine FDA. FDA Advisory No. 2025-05488Philippine FDA. FDA Advisory No. 2025-0549
Because the products had not been evaluated, the agency said it could not guarantee their safety, quality, or efficacy, and warned that unauthorized products may contain harmful ingredients or impurities. It prohibited the manufacture, importation, sale, distribution, and promotion of both products until they receive proper authorization, and directed regional offices and law enforcement to remove them from the market.8Philippine FDA. FDA Advisory No. 2025-0549
Better Business Bureau Complaints
Medicube holds an F rating from the Better Business Bureau and is not BBB-accredited. Consumers filed 30 complaints against the company over the three years preceding June 2026, and Medicube failed to respond to 22 of them.9Better Business Bureau. Medicube BBB Business Profile The complaints fall roughly into three groups.
Product complaints describe adverse skin reactions, items arriving damaged or opened, foul odors, and skincare devices that malfunctioned or were ineffective. Service complaints center on poor communication, difficulty getting returns or refunds processed, and reports of customers being muted during TikTok live sessions after voicing dissatisfaction. Shipping complaints describe delays well beyond the stated three-to-seven business day window, along with undisclosed customs fees at checkout.3Better Business Bureau. Medicube BBB Complaints
When Medicube did respond, the company frequently denied responsibility for orders placed through third-party resellers such as YesStyle, telling customers to contact their original point of purchase. Customers reporting shipping delays said they received generic replies citing high order volumes without concrete timelines.3Better Business Bureau. Medicube BBB Complaints
Who Owns Medicube
Medicube is one of six brands operated by APR Corporation, a Seoul-based beauty company founded in 2014 by CEO Byung Hoon Kim. APR’s other brands include Aprilskin and Forment, and roughly 80 percent of its revenue comes from overseas sales.10WIPO. From Korean Skincare to Beauty Tech: APR Global Trademark Strategy Beyond the advertising suspension, company records indicate APR has faced a fine tied to a late filing on a capital increase and has contended with a surge in counterfeit Medicube products on the market.11KoreaWho. Kim Byunghoon Profile